GRCE
Income statement / Annual
Last year (2023), Grace Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Grace Therapeutics, Inc.'s net income was -$12.85 M.
See Grace Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
02/29/2016 |
02/28/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$196,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$27,787.00 |
$216,288.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$76,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$60,082.00
|
$187,896.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$120,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$32,294.06
|
$28,392.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.61
|
0
|
0
|
0
|
0
|
-1.16
|
0.13
|
| Research and Development Expenses |
$4.68 M
|
$9.97 M
|
$5.56 M
|
$4.17 M
|
$15.97 M
|
$29.37 M
|
$12.13 M
|
$0.00
|
$5.58 M
|
$7.05 M
|
| General & Administrative Expenses |
$6.45 M
|
$8.08 M
|
$9.67 M
|
$5.51 M
|
$5.80 M
|
$3.80 M
|
$3.12 M
|
$0.00
|
$1.51 M
|
$2.86 M
|
| Selling & Marketing Expenses |
$194,000.00
|
$136,000.00
|
$116,000.00
|
$1.14 M
|
$2.67 M
|
$494,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.64 M
|
$8.21 M
|
$9.78 M
|
$6.66 M
|
$8.46 M
|
$4.29 M
|
$3.12 M
|
$0.00
|
$1.51 M
|
$2.86 M
|
| Other Expenses |
$1.53 M
|
$33.97 M
|
$249,000.00
|
$5.71 M
|
$0.00
|
$741,000.00
|
$0.00
|
$0.00
|
-$60,082.21
|
-$187,896.93
|
| Operating Expenses |
$12.85 M
|
$52.16 M
|
$15.59 M
|
$16.54 M
|
$24.44 M
|
$34.41 M
|
$15.25 M
|
$0.00
|
$7.03 M
|
$9.72 M
|
| Cost And Expenses |
$12.85 M
|
$52.16 M
|
$15.59 M
|
$16.62 M
|
$24.44 M
|
$34.41 M
|
$15.25 M
|
$0.00
|
$7.09 M
|
$9.91 M
|
| Interest Income |
$911,000.00
|
$246,000.00
|
$77,000.00
|
$107,000.00
|
$336,000.00
|
$358,000.00
|
$55,753.00
|
$0.00
|
$53,870.00
|
$69,534.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$264,000.00
|
$247,000.00
|
$278,000.00
|
$283,411.00
|
$0.00
|
$1,476.00
|
$3,244.96
|
| Depreciation & Amortization |
$11,000.00
|
$124,000.00
|
$0.00
|
$924,000.00
|
$2.32 M
|
$2.33 M
|
$2.07 M
|
$0.00
|
$1.77 M
|
$1.87 M
|
| EBITDA |
-$11.33 M |
-$18.12 M |
-$15.34 M |
-$9.79 M |
-$22.95 M |
-$36.76 M |
-$14.30 M |
$0.00 |
-$2.89 M |
-$8.04 M |
| EBITDA Ratio |
0
|
0
|
0
|
-49.96
|
0
|
0
|
0
|
0
|
-104.16
|
-37.17
|
| Operating Income Ratio |
0
|
0
|
0
|
-83.77
|
0
|
0
|
0
|
0
|
-255.27
|
-45.8
|
| Total Other Income/Expenses Net |
-$1.83 M
|
$184,000.00
|
$5.12 M
|
-$3.26 M
|
-$1.08 M
|
-$4.96 M
|
-$1.40 M
|
$0.00
|
$2.43 M
|
$8.58 M
|
| Income Before Tax |
-$14.69 M
|
-$51.97 M
|
-$10.47 M
|
-$19.68 M
|
-$25.51 M
|
-$39.37 M
|
-$16.65 M
|
$0.00
|
-$4.66 M
|
-$1.32 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
0
|
-167.76
|
-6.12
|
| Income Tax Expense |
-$1.83 M
|
-$9.54 M
|
-$648,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$12.85 M
|
-$42.43 M
|
-$9.82 M
|
-$19.68 M
|
-$25.51 M
|
-$39.37 M
|
-$16.65 M
|
$0.00
|
-$4.66 M
|
-$1.32 M
|
| Net Income Ratio |
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
0
|
-167.76
|
-6.12
|
| EPS |
-1.73 |
-5.71 |
-1.62 |
-7.98 |
-14.4 |
-46.9 |
-58.96 |
0 |
-27.94 |
-9.59 |
| EPS Diluted |
-1.73 |
-5.71 |
-1.62 |
-7.98 |
-14.4 |
-46.9 |
-58.96 |
0 |
-27.94 |
-9.59 |
| Weighted Average Shares Out |
$7.44 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$1.13 M
|
$364,302.00
|
$0.00
|
$222,082.00
|
$221,202.00
|
| Weighted Average Shares Out Diluted |
$7.44 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$1.13 M
|
$364,302.00
|
$0.00
|
$222,082.00
|
$221,202.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
